<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098451</article-id><article-id pub-id-type="doi">10.3389/fcimb.2025.1564488</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Comprehensive analysis of culture-negative periprosthetic joint infection with metagenomic next-generation sequencing</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Lan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jiayu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2164301/overview"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Canhong</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Juncheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Baijian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Zida</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2267352/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Jianhua</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Mingzhong</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Wenbo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Wenming</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/950166/overview"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fang</surname><given-names>Xinyu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2094331/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Orthopaedic Surgery, The First Affiliated Hospital of Fujian Medical University</institution>, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Orthopaedic Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University</institution>, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Fujian Provincial Institute of Orthopedics, the First Affiliated Hospital, Fujian Medical University</institution>, <addr-line>Fuzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Department of Orthopedic Surgery, Quanzhou First Affiliated Hospital of Fujian Medical University</institution>, <addr-line>Quanzhou</addr-line>, <country>China</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Department of Orthopedic Surgery, Affiliated Hospital of Putian University</institution>, <addr-line>Putian</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Yao Liu, National Institutes of Health (NIH), United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: William R. Schwan, University of Wisconsin&#x02013;La Crosse, United States</p><p>Arne Kienzle, Charit&#x000e9; University Medicine Berlin, Germany</p></fn><corresp id="fn001">*Correspondence: Xinyu Fang, <email xlink:href="mailto:fangxinyu0417@fjmu.edu.cn">fangxinyu0417@fjmu.edu.cn</email>; Wenming Zhang, <email xlink:href="mailto:zhangwm0591@fjmu.edu.cn">zhangwm0591@fjmu.edu.cn</email>; Wenbo Li, <email xlink:href="mailto:liwenbo350001@163.com">liwenbo350001@163.com</email>
</corresp><fn fn-type="other" id="fn003"><p>&#x02020;These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>1564488</elocation-id><history><date date-type="received"><day>21</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Lin, Li, Zhang, Li, Wu, Huang, Lv, Liu, Li, Zhang and Fang</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Lin, Li, Zhang, Li, Wu, Huang, Lv, Liu, Li, Zhang and Fang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objective</title><p>This study aimed to identify the risk factors and microbial profiles of patients with culture-negative periprosthetic joint infection (PJI) using metagenomic next generation sequencing (mNGS) and to compare the clinical characteristics and treatment outcomes of culture-negative PJI (CN PJI) with culture-positive PJI (CP PJI).</p></sec><sec><title>Methods</title><p>A retrospective analysis was conducted on 223 patients who met the International Consensus Meeting criteria for PJI and underwent surgical treatment at our hospital between February 2013 and January 2023. Clinical and follow-up data, including microbiological culture results and mNGS findings, were collected. Based on culture results, patients were divided into the CP PJI and CN PJI groups. Risk factors and microbial profiles of CN PJI patients were summarized with the aid of mNGS results. Differences in clinical characteristics and treatment outcomes between the two groups were also analyzed.</p></sec><sec><title>Results</title><p>Among the 223 patients, 168 were in the CP PJI group, and 55 were in the CN PJI group. Risk factors for negative cultures included polymicrobial infections, infections caused by rare pathogens, and prolonged antibiotic use prior to sampling. In the CN PJI group, over a quarter of cases involved polymicrobial infections (25.5%) or rare pathogen infections (38.2%), with <italic>Mycoplasma</italic> sp. being the most frequently identified rare pathogen (7.2%). Compared to the CP PJI group, the CN PJI group exhibited distinctly longer hospital stays (<italic>P</italic>&#x0003c;0.001), extended antibiotic use (<italic>P</italic>=0.02), and a higher rate of antibiotic-related complications (<italic>P</italic>=0.026). However, no significant difference was noted in reinfection rates between the two groups (<italic>P</italic>=0.412).</p></sec><sec><title>Conclusion</title><p>CN PJI presents a unique microbial spectrum and distinct clinical therapeutic characteristics. mNGS offers a more comprehensive understanding of infecting microorganisms, particularly those often missed by conventional culture techniques. With advancements in sample collection, optimized culture methods, molecular diagnostic tools, and early targeted therapies, CN PJI may achieve clinical outcomes comparable to CP PJI.</p></sec></abstract><kwd-group><kwd>periprosthetic joint infection</kwd><kwd>negative microbiological cultures</kwd><kwd>metagenomic next-generation sequencing</kwd><kwd>microbiology</kwd><kwd>risk factors</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China (2023ZQNZD007) and the Natural Science Foundation of Fujian Province (2024J011457, 2023J011778).</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="45"/><page-count count="11"/><word-count count="5289"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Clinical Microbiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>With the aging population, the prevalence of severe joint degeneration has been steadily rising. Total joint replacement is widely recognized as an effective intervention to effectively improve the quality of life in patients with advanced joint diseases, alleviating pain and functional impairments associated with these conditions (<xref rid="B39" ref-type="bibr">Walker et&#x000a0;al., 2002</xref>; <xref rid="B4" ref-type="bibr">Bumpass and Nunley, 2012</xref>). Despite these remarkable benefits, periprosthetic joint infection (PJI) remains a severe complication and the leading cause of failure in both primary and revision joint replacement surgeries (<xref rid="B3" ref-type="bibr">Bozic et&#x000a0;al., 2010</xref>; <xref rid="B21" ref-type="bibr">Illingworth et&#x000a0;al., 2013</xref>). The incidence of PJI is reported to range from 1-3% for primary joint replacements and 4-12% for revision surgeries (<xref rid="B7" ref-type="bibr">Della Valle et&#x000a0;al., 2011</xref>; <xref rid="B24" ref-type="bibr">Kapadia et&#x000a0;al., 2016</xref>), with a mortality rate as high as 20% within 5 years of diagnosis (<xref rid="B32" ref-type="bibr">Patel, 2023</xref>). Once it occurs, it not only leads to the involvement of bone and soft tissues (e.g., the patellar tendon), affecting joint function, but also imposes significant physical, psychological, and economic burdens on patients.</p><p>Accurate identification of the causative pathogen is essential for guiding effective, targeted antibiotic therapy for PJI. Currently, microbial culture of infected tissue and synovial fluid is deemed as the gold standard for pathogen diagnosis. However, studies have documented that microbial cultures yield negative results in up to 42% of PJI cases (<xref rid="B35" ref-type="bibr">Tan et&#x000a0;al., 2018</xref>; <xref rid="B14" ref-type="bibr">Goswami et&#x000a0;al., 2022</xref>). In such culture-negative PJI (CN PJI) cases, the inability to identify the pathogen poses a significant challenge for clinicians, making it difficult to provide targeted antimicrobial therapy. This lack of targeted treatment is a major concern, as CN PJI patients are reported to have recurrence and reoperation rates more than 4 times higher than those of patients with CP PJI (<xref rid="B27" ref-type="bibr">Mortazavi et&#x000a0;al., 2011</xref>; <xref rid="B14" ref-type="bibr">Goswami et&#x000a0;al., 2022</xref>). The recurrence of CN PJI involves the following primary mechanisms: (1) Pathogen persistence via biofilm formation on implant surfaces, which shields bacteria from host immune defenses and antibiotic clearance, thereby promoting chronic/recurrent infections (<xref rid="B38" ref-type="bibr">Van Roy et&#x000a0;al., 2024</xref>); (2) Prolonged or inappropriate broad-spectrum antibiotic use disrupts commensal microbiota homeostasis (dysbiosis), thus enhancing host susceptibility to colonization by opportunistic pathogens (<xref rid="B23" ref-type="bibr">Jandl et&#x000a0;al., 2024</xref>). PJI is a complex infectious disease, and the occurrence of CN PJI is influenced by multiple factors. One critical factor is the prolonged use of antibiotics before sampling, which has been shown to distinctly increase the likelihood of culture-negative results (<xref rid="B2" ref-type="bibr">Berbari et&#x000a0;al., 2007</xref>). Other contributing factors include infections caused by low-virulence microorganisms, biofilm formation, insufficient sample volume, and improper or delayed transportation of specimens (<xref rid="B15" ref-type="bibr">Goswami and Parvizi, 2020</xref>).</p><p>The rapid advancement of molecular diagnostics has significantly improved the detection of pathogenic microorganisms in complex infectious diseases. Quantitative polymerase chain reaction (qPCR) facilitates precise microbial identification utilizing primers that are complementary to specific DNA sequences of target species. Furthermore, early studies have demonstrated the high sensitivity of qPCR in detecting microorganisms within biofilms (<xref rid="B34" ref-type="bibr">Stoodley et&#x000a0;al., 2011</xref>; <xref rid="B22" ref-type="bibr">Jacovides et&#x000a0;al., 2012</xref>). However, the primary limitation of qPCR lies in its inability to detect pathogens beyond a predetermined range, which greatly restricts its utility in diagnosing CN PJI (<xref rid="B6" ref-type="bibr">Chiu and Miller, 2019</xref>; <xref rid="B8" ref-type="bibr">Diao et&#x000a0;al., 2022</xref>). Metagenomic next-generation sequencing (mNGS), on the other hand, is a high-throughput, unbiased screening method that combines advanced sequencing technology with bioinformatics analysis to comprehensively identify all known microorganisms (including bacteria, fungi, viruses, and parasites) in clinical samples (<xref rid="B12" ref-type="bibr">Fang et&#x000a0;al., 2020</xref>). This revolutionary approach broadens the scope of molecular diagnostic techniques, offering unprecedented value in diagnosing infectious agents, particularly in challenging cases of CN PJI (<xref rid="B36" ref-type="bibr">Tarabichi et&#x000a0;al., 2018a</xref>; <xref rid="B37" ref-type="bibr">Tarabichi et&#x000a0;al., 2018b</xref>; <xref rid="B14" ref-type="bibr">Goswami et&#x000a0;al., 2022</xref>).</p><p>To date, reports on a comprehensive analysis of CN PJI based on larger sample sizes are scarce. This study focused on this gap by analyzing the clinical data of a substantial cohort of CN PJI patients treated at our center. Utilizing molecular diagnostic techniques such as mNGS, we conducted an integrated analysis of the potential risk factors, microbial profiles, and clinical treatment characteristics of CN PJI. Our goal is to provide surgeons with deeper insights into the diagnostic and therapeutic nuances of CN PJI.</p></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>Patient selection</title><p>With the approval of the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (MRCTA, FMU ECFAH 2018 [026]), we retrospectively collected clinical data from 223 PJI patients who underwent revision surgery at our center between February 2013 to January 2023. All patients underwent joint replacement surgery prior to developing PJI, including 94 total knee arthroplasty (TKA), 14 unicompartmental knee arthroplasty (UKA), 84 total hip arthroplasty (THA), and 31 hip hemiarthroplasties. Upon admission, all patients underwent a comprehensive evaluation, which included serum inflammatory markers [white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), synovial fluid polymorphonuclear neutrophil and synovial fluid WBC (SF-WBC)]. The diagnosis of PJI was validated through at least two senior orthopedic surgeons, two senior infectious disease specialists, and one senior microbiologist in accordance with the criteria outlined by the Musculoskeletal System Infection Association (<xref rid="B31" ref-type="bibr">Parvizi et&#x000a0;al., 2011</xref>). Inclusion criteria were: 1. patients diagnosed with PJI; 2. patients who provided informed consent; 3. patients with complete clinical data. The exclusion criteria were: 1. patients with comorbid malignant tumors were excluded to avoid immune dysfunction or treatment-related biases; 2. those with other active infections were excluded to isolate inflammatory and microbiological profiles specific to PJI; 3. culture-negative and mNGS-negative or without mNGS testing were excluded to ensure all included PJIs had definitive pathogen identification; 4. follow-up period of less than 2 years.</p></sec><sec id="s2_2"><label>2.2</label><title>Specimen collection and microbial culture</title><p>Periprosthetic tissue samples were collected from five different sites and minced. Tissue homogenates were prepared by an automatic high-speed tissue homogenizer (JXFSTPRP24, Jingxin Industrial, Shanghai, China) and inoculated onto Columbia blood agar plates (HBPM0124-15, Haibo Biotechnology, Qingdao, China) under both anaerobic and aerobic conditions. For liquid specimens (synovial fluid, wound exudate, etc.), the specimens were directly introduced into BACTEC Plus aerobic (442192, Becton-Dickinson, Franklin Lakes, New Jersey, USA) and anaerobic vials (442193, Becton-Dickinson, Franklin Lakes, New Jersey, USA) and incubated in an automated thermostat (Bactec 9050, Becton-Dickinson, Franklin Lakes, New Jersey, USA) at 37&#x000b0;C with 6% CO<sub>2</sub> for 14 days. Prosthetic components removed during surgery (such as knee pads, hip liners, etc.) were placed in 400 ml of sterile saline and treated with ultrasonic vibration (40 Hz, 5 min) to disrupt the biofilm and generate ultrasonic lysate. The lysate was centrifuged, and the supernatant was discarded. The resulting sediment was pelleted by centrifugation at 10,000 x g for 15 minutes at 4&#x000b0;C. The resulting sediment was inoculated into aerobic culture bottles (442192, Becton-Dickinson, Franklin Lakes, New Jersey, USA) and anaerobic culture bottles (442193, Becton-Dickinson, Franklin Lakes, New Jersey, USA) for incubation under the same conditions (37&#x000b0;C, 6% CO<sub>2</sub>, 14 days).</p></sec><sec id="s2_3"><label>2.3</label><title>mNGS with results interpretation</title><p>Specimen pre-treatment was consistent with that described in microbiological culture and mNGS was performed following the protocol described previously (<xref rid="B19" ref-type="bibr">Huang et&#x000a0;al., 2020</xref>). Briefly, DNA was extracted from the samples utilizing the TIANamp Micro DNA kit (DP316, Tiangen, China), which was completely fragmented into small fragments of about 200&#x02013;300 bp in size. Rolling circle amplification was then used to replicate DNA, forming DNA nanospheres. These nanospheres were loaded onto the sequencing chip and sequenced utilizing the BGISEQ-500 platform (UWIC, China). The human genome sequence (Hg19) was filtered out utilizing Burrows-Wheeler alignment, and the remaining sequencing data were compared with microbial databases for taxonomic classification of microorganisms.</p><p>The definition of rare pathogens was based on previous reports (<xref rid="B1" ref-type="bibr">Anagnostakos et&#x000a0;al., 2021</xref>; <xref rid="B26" ref-type="bibr">Lyu et&#x000a0;al., 2024</xref>). For cases where microbial cultures were negative but mNGS results were positive, the following criteria were adopted to test whether the mNGS result represented a &#x0201c;true positive&#x0201d; (<xref rid="B10" ref-type="bibr">Ding et&#x000a0;al., 2024</xref>): 1. The pathogen identified by mNGS has been previously reported to cause bone and joint infections, and the clinical characteristics are consistent with such infections; 2. A third diagnostic method, such as 16S rRNA sequencing, confirms the same pathogen identified by mNGS. For the 16S rRNA sequencing technique, briefly, we extracted total microbial DNA from synovial fluid, sonicate prosthetic fluid, and tissue homogenate specimens using the TIANamp Micro DNA Kit (CDP316, Tiangen Biotech, China). PCR amplification targeting the V4 region of the bacterial 16S rRNA gene was performed in a 25 &#x003bc;l reaction volume with the TopTaq DNA Polymerase kit (AP151-13, TransGen Biotech, China), using primers 515f (5&#x02032;-GTGCCAGCMGCCGCGGTAA-3&#x02032;) and 806r (5&#x02032;-GGACTACHVGGGTWTCTAAT-3&#x02032;); 3. Targeted antibiotic therapy is determined to be effective by at least 3 senior clinicians.</p></sec><sec id="s2_4"><label>2.4</label><title>Surgical method selection</title><p>All patients were treated according to the Tsukayama classification system (<xref rid="B20" ref-type="bibr">Hulleman et&#x000a0;al., 2023</xref>). Briefly, for patients with early postoperative PJI or acute hematogenous dissemination of PJI (Tsukayama Type II/III), debridement with implant retention (DAIR) was typically adopted. For patients with Tsukayama Type I/IV PJI, without sinus tract formation and infections caused by non-multi-resistant organisms, a one-stage revision was chosen. In chronic PJI patients (chronic Tsukayama Type IV) with sinus tract formation, multidrug-resistant pathogens, and poor soft tissue coverage, a two-stage revision was generally preferred. Patient preferences also played a role in determining the final surgical strategy. The surgical procedures were implemented by a consistent treatment team at our center.</p></sec><sec id="s2_5"><label>2.5</label><title>Follow up</title><p>Patients were followed up every 3 months through outpatient visits and telephone calls for at least 2 years, with reinfection and mortality as the primary endpoints. Regular reviews were conducted for infection-related serum inflammatory markers, such as ESR and CRP. Infection control was assessed based on the Delphi consensus (<xref rid="B9" ref-type="bibr">Diaz-Ledezma et&#x000a0;al., 2013</xref>). Infection control was defined as the successful completion of treatment without infection-related complications or the need for reoperation. This definition ensures long-term eradication of the infection, rather than merely transient suppression.</p><p>Antibiotic-related complications were defined as follows (<xref rid="B44" ref-type="bibr">Xu et&#x000a0;al., 2022</xref>): 1. Myelosuppression: a WBC count above 4&#x000d7;10<sup>9</sup>/L prior to antibiotics, but below 3&#x000d7;10<sup>9</sup>/L during treatment; 2. Hepatic impairment: Elevation of hepatic function indexes [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] by more than 1.5 times the baseline levels prior to antibiotic administration; 3. renal impairment: An increase in serum creatinine by more than 1.5 times the normal baseline level before antibiotic use; 4. Gastrointestinal symptoms: Severe nausea, vomiting, and dyspepsia indicative of antibiotic-induced gastrointestinal disturbances. These laboratory results, along with clinical symptoms, were considered indicative of adverse effects on organ function due to antibiotic use.</p></sec><sec id="s2_6"><label>2.6</label><title>Statistical analysis</title><p>Continuous variables were first studied for normality utilizing the Kolmogorov-Smirnov test. Normally distributed variables are summarized as mean &#x000b1; standard deviation, and comparisons were made utilizing the independent-samples t-test. Non-normally distributed variables are reported as median (interquartile range), with the Mann-Whitney U test adopted for comparisons. Categorical variables were compared between groups employing the Chi-squared test or Fisher&#x02019;s exact test, as appropriate. Binary logistic regression analysis was performed to identify potential risk factors based on demographic data. Infection control during the follow-up period was assessed in both groups employing the Kaplan-Meier survival analysis. All statistical analyses were made utilizing SPSS 26.0 (IBM, USA), and <italic>P</italic> &#x0003c; 0.05 signified statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3_1"><label>3.1</label><title>Demographic characteristics</title><p>Our cohort consisted of 271 patients who met the 2018 International Consensus Meeting criteria (<xref rid="B30" ref-type="bibr">Parvizi et&#x000a0;al., 2018</xref>) for PJI and were hospitalized at the First Hospital of Fujian Medical University between February 2013 and January 2023. After applying the exclusion criteria, 223 patients were finally included (<xref rid="f1" ref-type="fig">
<bold>Figure&#x000a0;1</bold>
</xref>). Based on the results of microbiological cultures and mNGS of synovial fluid, prosthetic ultrasound fluid, and intraoperative tissue samples, 168 culture-positive patients were assigned to the CP PJI group, and 55 patients with negative routine cultures but positive mNGS results were included in the CN PJI group. The baseline characteristics of the two groups were similar, with no significant differences in age, gender, BMI, surgical site, Charlson comorbidity index (CCI), the presence or absence of preoperative invasive procedures, sinus tract formation, or preoperative serological tests (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>). However, relative to the CP PJI group, the CN PJI group had a higher proportion of multiple infections (<italic>P</italic>=0.042), infections caused by rare pathogens (<italic>P</italic>&#x0003c;0.001), and a longer duration of antibiotic use prior to sampling (<italic>P</italic>&#x0003c;0.001) (<xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>). These findings suggest that multiple infections, infection with rare pathogens, and prolonged antibiotic use prior to sampling may notably influence the results of microbial cultures.</p><fig position="float" id="f1"><label>Figure&#x000a0;1</label><caption><p>Flow chart of the inclusion, exclusion, and grouping of PJI cases in this study.</p></caption><graphic xlink:href="fcimb-15-1564488-g001" position="float"/></fig><table-wrap position="float" id="T1"><label>Table&#x000a0;1</label><caption><p>Comparison of characteristics between culture positive and culture negative groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">CP PJI (n=168)</th><th valign="top" align="left" rowspan="1" colspan="1">CN PJI (n=55)</th><th valign="top" align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">65.46 &#x000b1; 11.2</td><td valign="top" align="left" rowspan="1" colspan="1">68.00 &#x000b1; 11.8</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.153</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender (male/female)</td><td valign="top" align="left" rowspan="1" colspan="1">72/96</td><td valign="top" align="left" rowspan="1" colspan="1">26/29</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.567</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">24.56 &#x000b1; 3.19</td><td valign="top" align="left" rowspan="1" colspan="1">24.06 &#x000b1; 3.09</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.310</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Joint (hip/knee)</td><td valign="top" align="left" rowspan="1" colspan="1">88/80</td><td valign="top" align="left" rowspan="1" colspan="1">27/28</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.672</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCI</td><td valign="top" align="left" rowspan="1" colspan="1">2.48 &#x000b1; 1.35</td><td valign="top" align="left" rowspan="1" colspan="1">2.82 &#x000b1; 1.38</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.108</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PIP (y/n)</td><td valign="top" align="left" rowspan="1" colspan="1">112/56</td><td valign="top" align="left" rowspan="1" colspan="1">41/14</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.271</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sinus tract (y/n)</td><td valign="top" align="left" rowspan="1" colspan="1">42/126</td><td valign="top" align="left" rowspan="1" colspan="1">17/38</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.389</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Multiple infection (y/n)</td><td valign="top" align="left" rowspan="1" colspan="1">22/144</td><td valign="top" align="left" rowspan="1" colspan="1">15/40</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.016*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rare pathogen infection (y/n)</td><td valign="top" align="left" rowspan="1" colspan="1">18/150</td><td valign="top" align="left" rowspan="1" colspan="1">21/34</td><td valign="top" align="left" rowspan="1" colspan="1">P&#x0003c;0.001*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Prior use of antibiotics (days)</td><td valign="top" align="left" rowspan="1" colspan="1">3.43 &#x000b1; 4.17</td><td valign="top" align="left" rowspan="1" colspan="1">8.16 &#x000b1; 5.80</td><td valign="top" align="left" rowspan="1" colspan="1">P&#x0003c;0.001*</td></tr><tr><th valign="top" colspan="4" align="left" rowspan="1">Laboratory data</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WBC (&#x000d7;10<sup>9</sup>/l) (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">6.63 (5.39,8.65)</td><td valign="top" align="left" rowspan="1" colspan="1">6.44 (4.65,8.86)</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.468</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ESR (mm/h) (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">63.50 (40.00,89.75)</td><td valign="top" align="left" rowspan="1" colspan="1">41.00 (30.00,82.00)</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.062</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CRP (mg/l) (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">34.85 (12.40,67.35)</td><td valign="top" align="left" rowspan="1" colspan="1">19.83 (11.60,45.47)</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.059</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SF WBC (/ml) (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">10914.00 (4552.00,35429.50)</td><td valign="top" align="left" rowspan="1" colspan="1">12892.00 (3781.00,27391.00)</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.790</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SF PMN (%) (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">77.80 (67.00,89.48)</td><td valign="top" align="left" rowspan="1" colspan="1">74.80 (51.10,88.20)</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.051</td></tr></tbody></table><table-wrap-foot><fn><p>CP, culture positive; CN, culture negative; BMI, body mass index; CCI, Charlson comorbidity index; PIP, preoperative invasive procedures; WBC, white blood cell count; CRP, C-reaction protein; ESR, erythrocyte sedimentation rate; SF, synovial fluid; PMN, polymorphonuclear neutrophils; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_2"><label>3.2</label><title>Risk factors for CN PJI</title><p>Based on the findings illustrated in <xref rid="T1" ref-type="table">
<bold>Table&#x000a0;1</bold>
</xref>, we performed multivariate logistic regression to examine the impact of multiple infections, rare pathogen infections, and the duration of antibiotic use prior to sampling on the likelihood of negative microbiological cultures. The results demonstrated that multiple infections were linked to a 1.489-fold increase in the probability of negative microbiological cultures in PJI patients (OR=2.489, 95%CI [1.183-5.235], <italic>P</italic>=0.016). Patients infected with rare pathogens had a nearly fourfold increased risk of negative cultures compared to those infected with non-rare pathogens (OR=3.988, 95%CI [1.759-9.041], <italic>P</italic>&#x0003c;0.001). Additionally, each additional day of antibiotic use prior to sampling was linked to a 21.7% increased likelihood of a negative culture result (OR=1.211, 95%CI [1.114-1.317], <italic>P</italic>&#x0003c;0.001) (<xref rid="f2" ref-type="fig">
<bold>Figure&#x000a0;2</bold>
</xref>).</p><fig position="float" id="f2"><label>Figure&#x000a0;2</label><caption><p>Binary logistic regression analysis of risk factors associated with negative microbiological culture results in PJI.</p></caption><graphic xlink:href="fcimb-15-1564488-g002" position="float"/></fig></sec><sec id="s3_3"><label>3.3</label><title>Microbial profiles of CP PJI</title><p>In patients with culture-positive prosthetic joint infections (CP PJI), microbial cultures identified a total of 47 pathogens. The most common bacteria were <italic>Staphylococcus aureus</italic> (19.4%) and <italic>Staphylococcus epidermidis</italic> (20.3%) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#x000a0;1</bold>
</xref>), with Gram-negative bacteria detected in 14.8% of cases. Among the culture-positive patients, <italic>Staphylococcus aureus</italic> was categorized into methicillin-sensitive <italic>Staphylococcus aureus</italic> (MSSA) and methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA), accounting for 12.9% and 6.5% of the total, respectively. <italic>Staphylococcus epidermidis</italic>, another prevalent pathogen, was detected in 20.3% of cases. Among the Rare pathogens, <italic>Enterococcus faecalis</italic> had a relatively higher detection rate, found in 1.8% of patients. Other frequently detected Gram-positive bacteria included <italic>Staphylococcus capitis</italic> (3.2%), <italic>Staphylococcus haemolyticus</italic> (3.7%), and <italic>Staphylococcus hominis</italic> (0.9%). In terms of Gram-negative bacteria, <italic>Klebsiella pneumoniae</italic> and <italic>Escherichia coli</italic> were present in 4.1% and 3.7% of cases, respectively. Additionally, <italic>Pseud</italic>omonas aeruginosa and Enterobacter cloacae were detected in some patients. In addition, 13.1% (22/168) of CP PJI were infected with two or more pathogens. A median of 3 and a mean (and standard deviation) of 3.2 &#x000b1; 0.8 different pathogens were identified per case. Moreover, in 77.3% (17) of the 22 polymicrobial cases, multiple species defined as common (on the basis of a 5% incidence threshold) were present. <italic>Staphylococcus aureus</italic> and <italic>Staphylococcus epidermidis</italic> continued to be the pathogenic microorganisms with the highest frequency of occurrence in these patients with multiple infections.</p></sec><sec id="s3_4"><label>3.4</label><title>Microbial profiles of CN PJI</title><p>mNGS testing was performed on samples collected from infected sites in PJI patients with negative microbiological cultures. Among these samples, prosthetic ultrasound fluid accounted for the largest proportion (37.18%), followed by joint fluid (33.21%) and fresh tissue (29.61%) samples. In the entire CN PJI cohort, 69 pathogens were detected by mNGS, with the most common organisms being <italic>Staphylococcus epidermidis</italic> (13.0%) and <italic>Staphylococcus aureus</italic> (11.6%) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#x000a0;1</bold>
</xref>). Rare pathogen infections were identified in 38.2% of CN PJI patients, with 26 rare pathogens identified. The most common rare pathogens were <italic>Mycoplasma</italic> sp. (5, 7.2%), <italic>Candida parapsilosis</italic> (3, 4.3%) and <italic>Nontuberculous mycobacteria</italic> (3, 4.3%) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#x000a0;1</bold>
</xref>) (<xref rid="f3" ref-type="fig">
<bold>Figure&#x000a0;3</bold>
</xref>). The NTM species identified in this study comprised Mycobacterium colombiense (n=1), Mycobacterium abscessus (n=1), and Mycobacterium <italic>arupense</italic> (n=1), highlighting the diversity of atypical pathogens in culture-negative infections. In addition, 27.3% (15/55) of CN PJI were infected with two or more pathogens. A median of 2 and a mean (and standard deviation) of 2.1 &#x000b1; 0.3 different pathogens were identified per case. In 66.7% (10) of the 15 polymicrobial cases, multiple species defined as common (on the basis of a 5% incidence threshold) were present. The mNGS results showed that <italic>Staphylococcus aureus</italic> and <italic>Staphylococcus epidermidis</italic> were not only the pathogenic microorganisms with the highest frequency in CN PJI with multiple infection, but also with the highest mean relative abundance.</p><fig position="float" id="f3"><label>Figure&#x000a0;3</label><caption><p>Distribution of various rare pathogens in culture-negative PJI cases.</p></caption><graphic xlink:href="fcimb-15-1564488-g003" position="float"/></fig></sec><sec id="s3_5"><label>3.5</label><title>Comparison of clinical variables</title><p>No significant difference was noted concerning follow-up duration (<italic>P</italic>=0.251) or surgical approach (<italic>P</italic>=0.781) between the two groups. However, the median length of hospital stay was longer in the CN PJI group relative to the CP PJI group (<italic>P &#x0003c;</italic>0.001). The duration of antibiotic treatment was also longer in the CN PJI group (<italic>P</italic>=0.02), and the incidence of antibiotic complications was higher in this group as well (<italic>P</italic>=0.026). The one-year reinfection rate was 3.6% in the CP PJI group and 5.5% in the CN PJI group. These rates increased to 8.9% and 12.7%, respectively, over the two-year follow-up period. Most importantly, no notable difference was witnessed in the infection recurrence rate between the two cohorts during the 2-year follow-up, as assessed by Kaplan-Meier analysis (<italic>P</italic>=0.412) (<xref rid="T2" ref-type="table">
<bold>Table&#x000a0;2</bold>
</xref>) (<xref rid="f4" ref-type="fig">
<bold>Figure&#x000a0;4</bold>
</xref>).</p><table-wrap position="float" id="T2"><label>Table&#x000a0;2</label><caption><p>Comparison of outcomes between culture positive and culture negative groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variables</th><th valign="top" align="left" rowspan="1" colspan="1">CP PJI (n=168)</th><th valign="top" align="left" rowspan="1" colspan="1">CN PJI (n=55)</th><th valign="top" align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Follow-up period (months)</td><td valign="top" align="left" rowspan="1" colspan="1">40.96 &#x000b1; 15.67</td><td valign="top" align="left" rowspan="1" colspan="1">43.76 &#x000b1; 15.56</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.251</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Treatment, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">P=0.781</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;DAIR</td><td valign="top" align="left" rowspan="1" colspan="1">27 (16.1%)</td><td valign="middle" rowspan="3" colspan="2" align="left">7 (12.7%)<break/>
<break/>16 (29.1%)<break/>
<break/>32 (58.2%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;One-state revision</td><td valign="top" align="left" rowspan="1" colspan="1">43 (25.6%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Two-state revision</td><td valign="top" align="left" rowspan="1" colspan="1">98 (58.3%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Length of hospital stay, days (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (15,22)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (18,30)</td><td valign="top" align="left" rowspan="1" colspan="1">P&#x0003c;0.001*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Duration of antibiotic use, days (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">96 (61,112)</td><td valign="top" align="left" rowspan="1" colspan="1">101 (83,134)</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.02*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antibiotic complications (y/n)</td><td valign="top" align="left" rowspan="1" colspan="1">19/147</td><td valign="top" align="left" rowspan="1" colspan="1">13/42</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.026*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Reinfection (y/n)</td><td valign="top" align="left" rowspan="1" colspan="1">15/153</td><td valign="top" align="left" rowspan="1" colspan="1">7/48</td><td valign="top" align="left" rowspan="1" colspan="1">P=0.412</td></tr></tbody></table><table-wrap-foot><fn><p>CP, culture positive; CN, culture negative; DAIR, debridement with implant retention; IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="f4"><label>Figure&#x000a0;4</label><caption><p>Kaplan-Meier survival curve analysis comparing reinfection rates between the two groups. The shaded areas denote 95% CIs. CP, culture positive; CN, culture negative.</p></caption><graphic xlink:href="fcimb-15-1564488-g004" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>Targeted antibiotic therapy is crucial in the management of PJI, especially in cases of CN PJI. Inadequate or ineffective antibiotic selection can lead to delayed treatment response or even treatment failure, highlighting the critical significance of early and accurate pathogen diagnosis. Recent studies have underscored the significant value of molecular diagnostic techniques, particularly mNGS, in guiding effective antimicrobial therapy (<xref rid="B16" ref-type="bibr">Han et&#x000a0;al., 2019</xref>; <xref rid="B40" ref-type="bibr">Wang et&#x000a0;al., 2020</xref>). mNGS provides a comprehensive microbiological profile that may not be detected by conventional culture methods (<xref rid="B15" ref-type="bibr">Goswami and Parvizi, 2020</xref>). Additionally, although mNGS is more expensive than conventional culture methods, its ability to provide rapid and comprehensive pathogen detection may reduce overall healthcare costs by enabling timely and targeted antimicrobial therapy (<xref rid="B28" ref-type="bibr">Pan et&#x000a0;al., 2024</xref>). This, in turn, could potentially decrease the duration of hospitalization and the need for broad-spectrum antibiotics, contributing to better patient outcomes and lower treatment costs. Another key advantage of mNGS is its ability to detect microbial nucleic acids even when organisms are no longer viable due to prior antibiotic exposure (<xref rid="B25" ref-type="bibr">Langelier et&#x000a0;al., 2018</xref>). This is particularly relevant in clinical settings where prolonged antibiotic use before sampling can lead to false-negative cultures. While culture relies on bacterial viability, mNGS can identify pathogens from residual DNA/RNA fragments, improving diagnostic yield in pretreated patients. In our study, we analyzed microbiological culture and mNGS results from 223 PJI cases (including 55 CN PJIs) at our center. A comprehensive analysis of the risk factors, microbiological profiles, and clinical treatment characteristics of CN PJI was conducted. Our findings revealed that multiple infections, infections with rare pathogens, and the duration of antibiotic use prior to sampling were key risk factors associated with microbiological culture-negativity. Recent studies have similarly demonstrated that mNGS is more tolerant than microbial culture to pre-sampling antibiotic use. When antibiotics have been administered for &#x0003e;3 days, the detection rate of mNGS is significantly higher than that of conventional culture (<xref rid="B10" ref-type="bibr">Ding et&#x000a0;al., 2024</xref>). For atypical pathogens such as mycobacteria and fungi, culture often requires specialized growth media and stringent conditions, otherwise yielding negative results. Moreover, infections caused by these rare pathogens often present with distinctive clinical features (e.g., prior invasive procedures, sinus tracts, and high Charlson Comorbidity Index scores) (<xref rid="B26" ref-type="bibr">Lyu et&#x000a0;al., 2024</xref>). Therefore, in patients with a history of prolonged antibiotic therapy, clinical features suggestive of rare pathogen infection, suspected polymicrobial infections, or chronic PJI with suspected biofilm formation, we should maintain a high index of suspicion for culture-negative results. In such cases, while performing conventional cultures, mNGS should also be conducted to identify pathogens that may be missed by culture. For patients with CN PJI and positive mNGS results, systematic treatment should be initiated. First, the risk of false-positive mNGS results must be carefully evaluated. Subsequently, targeted antibiotic therapy should be selected based on the mNGS findings. Despite the relatively prolonged antibiotic treatment and higher incidence of complications in CN PJI, targeted therapy based on mNGS results achieved success rates comparable to those observed in CP PJI cases.</p><p>The diagnosis of pathogens can be particularly challenging in cases involving multiple infections (<xref rid="B17" ref-type="bibr">Hoffman et&#x000a0;al., 2006</xref>; <xref rid="B10" ref-type="bibr">Ding et&#x000a0;al., 2024</xref>). In the present study, multiple infections were detected in more than a quarter (25.5%) of CN PJI based on mNGS results. Previous research has shown that in infections associated with orthopedic surgery, the relatively limited nutrient and spatial resources of microbial ecosystems often result in the dominance of two or more microorganisms, which can interfere with the normal colonization and growth of other coexisting flora (<xref rid="B14" ref-type="bibr">Goswami et&#x000a0;al., 2022</xref>; <xref rid="B43" ref-type="bibr">Xie et&#x000a0;al., 2023</xref>). This competitive interaction, especially in complex infections like PJI, may result in a reduced microbial load, complicating the isolation of all pathogens utilizing conventional culture methods. When microbial abundance falls below the sensitivity threshold for culture, the likelihood of negative culture results increases. Recent studies have also shown that multiple infection PJI may promote a viable but nonculturable (VBNC) state in microorganisms, further contributing to negative culture outcomes (<xref rid="B14" ref-type="bibr">Goswami et&#x000a0;al., 2022</xref>).</p><p>Our comparative analysis revealed distinct microbial profiles between CP PJI and CN PJI groups, with important clinical implications. While <italic>Staphylococcus aureus</italic> (19.4% vs. 11.6%) and <italic>Staphylococcus epidermidis</italic> (20.3% vs. 13.0%) remained predominant in both groups, the CN PJI cohort demonstrated a 2.8-fold higher incidence of rare pathogens compared to CP PJI (38.2% vs. 10.7%). Notably, <italic>Mycoplasma</italic> sp<italic>ecies</italic> (7.2%) and <italic>non-tuberculous mycobacteria</italic> (4.3%) were exclusively detected in CN PJI cases through mNGS, organisms notoriously resistant to conventional culture due to their fastidious growth requirements. This disparity may explain the observed differences in initial treatment strategies&#x02014;the CN PJI group&#x02019;s prolonged antibiotic duration (<italic>P</italic>=0.02) likely reflects attempts at empirical coverage for these culture-elusive pathogens. Interestingly, gram-negative pathogens showed distinct distribution patterns. Although <italic>Escherichia coli</italic> was exclusively cultured in CP PJI (3.7%), CN PJI cases revealed unexpected gram-negative organisms like <italic>Stenotrophomonas maltophilia</italic> (2.9%) and <italic>Pseudomonas monteilii</italic> (2.9%), which are frequently associated with biofilm formation and antibiotic resistance. This microbial diversity in CN PJI aligns with the higher complication rates observed (<italic>P</italic>=0.026), as these organisms often require specific antimicrobial regimens not typically included in empirical protocols. Another key factor leading to negative microbiological cultures in PJI is infection with rare pathogens (<xref rid="B1" ref-type="bibr">Anagnostakos et&#x000a0;al., 2021</xref>; <xref rid="B18" ref-type="bibr">Huang et&#x000a0;al., 2023</xref>; <xref rid="B26" ref-type="bibr">Lyu et&#x000a0;al., 2024</xref>). Consistent with previous studies, the most common microorganisms identified in our CN PJI cohort were <italic>Staphylococcus epidermidis</italic> (13.0%) and <italic>Staphylococcus aureus</italic> (11.6%) (<xref rid="B14" ref-type="bibr">Goswami et&#x000a0;al., 2022</xref>). In addition, more than one-third (38.2%) of CN PJI cases in this cohort were linked to rare pathogens, a notably higher proportion than in the CP PJI group. Routine cultures have been shown to identify common microorganisms in up to 73.8% of cases, but culture positivity for rare pathogens is much lower, at just 53.1% (<xref rid="B26" ref-type="bibr">Lyu et&#x000a0;al., 2024</xref>). Among the rare pathogens, <italic>Mycoplasma</italic> sp. was the most frequently detected in our cohort. <italic>Mycoplasma</italic> sp. is a common colonizer of the respiratory and genitourinary tracts and can cause PJI following invasive procedures, such as catheterization. The challenging culture conditions for <italic>Mycoplasma</italic> sp., including the need for specialized media and a prolonged incubation period of up to 3 weeks (<xref rid="B33" ref-type="bibr">Rieber et&#x000a0;al., 2019</xref>), combined with the relatively low incidence of <italic>Mycoplasma</italic> sp. PJI, often result in missed diagnoses. Similarly, while <italic>non-tuberculous mycobacteria</italic> (NTM) can grow under routine culture conditions, they are slow-growing and require prolonged incubation times to be detected (<xref rid="B13" ref-type="bibr">Forbes et&#x000a0;al., 2018</xref>). As a result, culture-positive results for NTM are difficult to obtain unless NTM infection is specifically suspected. As a high-throughput and highly sensitive sequencing technology, mNGS is invaluable in identifying pathogens in rare PJI cases. For atypical pathogens (<italic>Mycoplasma</italic> sp., NTM or fungi, etc.), in previous studies, our center proposed a standardized and optimized diagnostic protocol for mNGS. This protocol was refined through the following measures: (1) Optimization of culture conditions (e.g., extending incubation periods to 3 weeks and employing SP4 media for Mycoplasma spp. based on preliminary mNGS findings); (2) Integration of pathogen abundance thresholds with clinical symptom assessment (localized erythema, systemic inflammatory responses) to exclude low-abundance contaminants; (3) Implementation of iterative validation through repeated 16S rRNA sequencing or culture for cases with discordant mNGS results and clinical manifestations (<xref rid="B45" ref-type="bibr">Zhang et&#x000a0;al., 2022</xref>; <xref rid="B5" ref-type="bibr">Cai et&#x000a0;al., 2023</xref>).</p><p>In cases of CN PJI, the lack of reliable pathogen information at the early stage often leads clinicians to resort to broad-spectrum antibiotics or combination therapy, such as non-targeted treatment with antibiotics like vancomycin and meropenem. However, as shown in this study, over one-third of CN PJI patients had infections caused by rare pathogens, which are often resistant to coverage by broad-spectrum antibiotics. This resistance increases the risk of adverse events (<xref rid="B42" ref-type="bibr">Xiang and Lu, 2019</xref>). For example, <italic>Mycoplasma</italic> sp., which lacks a cell wall, is not susceptible to vancomycin, but is effectively treated with tetracyclines or quinolones (<xref rid="B41" ref-type="bibr">Wang et&#x000a0;al., 2021</xref>). Similarly, NTM requires targeted anti-mycobacterial therapy, and their strong biofilm-forming ability makes it more resistant to antibiotics once a biofilm is established (<xref rid="B29" ref-type="bibr">Park et&#x000a0;al., 2014</xref>). Although the delay in obtaining sufficient pathogen information early on initially hampers disease management, a high clinical success rate was finally achieved after using mNGS for pathogen identification and administering targeted antibiotics. Therefore, we recommend performing mNGS as early as possible when confronted with high-risk PJI cases that yield negative culture results. For example, preoperative synovial fluid can be tested utilizing mNGS to obtain comprehensive pathogen data early on (<xref rid="B11" ref-type="bibr">Fang et&#x000a0;al., 2021</xref>), which can then be verified through optimized culture methods or 16S rRNA sequencing. Although this approach may increase treatment costs, it provides significant value by reducing adverse events and improving treatment success rates.</p><p>Despite the valuable findings of this study, there are several limitations that should be acknowledged. First, as a single-center retrospective study, it is subject to biases, despite enabling comparative analysis. Specifically, in cases of CN PJI, the decision to choose subsequent treatments based on culture or mNGS results could introduce selection bias, which may affect the final comparison of clinical outcomes. Second, due to sample selection bias and the varying sensitivity of mNGS across different sample types, the results of mNGS could differ depending on the sample analyzed. We also classified microorganisms with the highest abundance as the dominant flora, but when multiple samples from the same patient yield different results, the interpretation of these findings requires guidance from experienced microbiologists, which may introduce further bias. Third, this study excluded cases of PJI with negative results from both molecular diagnostic methods, such as mNGS, and conventional culture. However, clinicians frequently encounter cases where no effective pathogen information is obtained, which can lead to treatment failure. Therefore, further research into the risk factors, clinical characteristics, and treatment outcomes of such patients is of significant clinical importance. Finally, this study mainly addressed the mid-term treatment outcomes of CN PJI and CP PJI patients who received mNGS-based targeted therapy. Future studies should extend the follow-up period to determine potential disparities in long-term clinical outcomes between the two cohorts. These issues warrant further investigation through multi-center, completely randomized trials and extended clinical follow-up to address them comprehensively.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>Overall, CN PJI represents a distinct subset of infections with unique risk factors, microbial profiles, and clinical management considerations. Specifically, our study identified multiple infections, the presence of rare pathogens, and the duration of antibiotic use prior to sampling as key risk factors for CN PJI based on mNGS results. Although negative culture results often lead clinicians to initially treat with broad-spectrum antibiotics, resulting in prolonged antibiotic use, subsequent targeted therapy based on mNGS results does not show a significant difference in infection control rates when compared to CP PJI, which is diagnosed and treated according to the &#x0201c;gold standard&#x0201d; culture method. Given these findings, clinicians should tailor microbiological treatment strategies to the individual patient&#x02019;s circumstances. In cases of CN PJI, we recommend the integration of molecular diagnostics, such as mNGS, to optimize culture methods, facilitate early identification of causative organisms, and enable the timely development of targeted therapeutic strategies. This approach can help avoid the pitfalls of empirical treatment when the causative organism is unidentified. Nonetheless, further research is needed to determine the most effective strategies for diagnosing and treating CN PJI.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thanks the support of the below talent program: Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare (2023ZQNRCYX-FXY). The First Affiliated Hospital of Fujian Medical University Excellent Talent Program (YYXQN-FXY2022, YJCRC-B-ZWM2024).</p></ack><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the First Affiliated Hospital of Fujian Medical University Ethics Committee (MRCTA, FMU ECFAH 2018 [026]). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>LL: Writing &#x02013; original draft, Validation, Visualization. JLi: Project administration, Writing &#x02013; original draft. CZ: Investigation, Writing &#x02013; original draft. JL: Software, Writing &#x02013; original draft. BW: Data curation, Writing &#x02013; original draft. ZH: Methodology, Writing &#x02013; original draft. JLv: Formal Analysis, Writing &#x02013; original draft. ML: Formal Analysis, Writing &#x02013; original draft. WL: Validation, Writing &#x02013; original draft. WZ: Resources, Writing &#x02013; review &#x00026; editing. XF: Funding acquisition, Resources, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s13"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2025.1564488/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fcimb.2025.1564488/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Table1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anagnostakos</surname><given-names>K.</given-names></name><name><surname>Grzega</surname><given-names>C.</given-names></name><name><surname>Sahan</surname><given-names>I.</given-names></name><name><surname>Geipel</surname><given-names>U.</given-names></name><name><surname>Becker</surname><given-names>S. L.</given-names></name></person-group> (<year>2021</year>). <article-title>Occurrence of rare pathogens at the site of periprosthetic hip and knee joint infections: A retrospective, single-center study</article-title>. <source>Antibiotics (Basel Switzerland)</source>
<volume>10</volume> (<issue>7</issue>), <fpage>882</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/antibiotics10070882</pub-id>
<pub-id pub-id-type="pmid">34356802</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berbari</surname><given-names>E. F.</given-names></name><name><surname>Marculescu</surname><given-names>C.</given-names></name><name><surname>Sia</surname><given-names>I.</given-names></name><name><surname>Lahr</surname><given-names>B. D.</given-names></name><name><surname>Hanssen</surname><given-names>A. D.</given-names></name><name><surname>Steckelberg</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Culture-negative prosthetic joint infection</article-title>. <source>Clin. Infect. diseases: an Off. Publ. Infect. Dis. Soc. America</source>
<volume>45</volume>, <fpage>1113</fpage>&#x02013;<lpage>1119</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1086/522184</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bozic</surname><given-names>K. J.</given-names></name><name><surname>Kurtz</surname><given-names>S. M.</given-names></name><name><surname>Lau</surname><given-names>E.</given-names></name><name><surname>Ong</surname><given-names>K.</given-names></name><name><surname>Chiu</surname><given-names>V.</given-names></name><name><surname>Vail</surname><given-names>T. P.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>The epidemiology of revision total knee arthroplasty in the United States</article-title>. <source>Clin. orthopaedics related Res.</source>
<volume>468</volume>, <fpage>45</fpage>&#x02013;<lpage>51</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11999-009-0945-0</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bumpass</surname><given-names>D. B.</given-names></name><name><surname>Nunley</surname><given-names>R. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Assessing the value of a total joint replacement</article-title>. <source>Curr. Rev. musculoskeletal Med.</source>
<volume>5</volume>, <fpage>274</fpage>&#x02013;<lpage>282</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s12178-012-9139-6</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Optimization and standardization of mNGS-based procedures for the diagnosis of Mycoplasma periprosthetic joint infection: A novel diagnostic strategy for rare bacterial periprosthetic joint infection</article-title>. <source>Front. Cell. infection Microbiol.</source>
<volume>13</volume>, <elocation-id>1089919</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2023.1089919</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C. Y.</given-names></name><name><surname>Miller</surname><given-names>S. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Clinical metagenomics</article-title>. <source>Nat. Rev. Genet.</source>
<volume>20</volume>, <fpage>341</fpage>&#x02013;<lpage>355</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41576-019-0113-7</pub-id>
<pub-id pub-id-type="pmid">30918369</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Della Valle</surname><given-names>C.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name><name><surname>Bauer</surname><given-names>T. W.</given-names></name><name><surname>DiCesare</surname><given-names>P. E.</given-names></name><name><surname>Evans</surname><given-names>R. P.</given-names></name><name><surname>Segreti</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>American Academy of Orthopaedic Surgeons clinical practice guideline on: the diagnosis of periprosthetic joint infections of the hip and knee</article-title>. <source>J. Bone Joint surgery. Am. volume</source>
<volume>93</volume>, <fpage>1355</fpage>&#x02013;<lpage>1357</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2106/JBJS.9314ebo</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diao</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Metagenomics next-generation sequencing tests take the stage in the diagnosis of lower respiratory tract infections</article-title>. <source>J. advanced Res.</source>
<volume>38</volume>, <fpage>201</fpage>&#x02013;<lpage>212</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.jare.2021.09.012</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diaz-Ledezma</surname><given-names>C.</given-names></name><name><surname>Higuera</surname><given-names>C. A.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus</article-title>. <source>Clin. orthopaedics related Res.</source>
<volume>471</volume>, <fpage>2374</fpage>&#x02013;<lpage>2382</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11999-013-2866-1</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Shedding light on negative cultures in osteoarticular infections: leveraging mNGS to unravel risk factors and microbial profiles</article-title>. <source>Front. Cell. infection Microbiol.</source>
<volume>14</volume>, <elocation-id>1457639</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2024.1457639</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Mei</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Optimizing culture methods according to preoperative mNGS results can improve joint infection diagnosis</article-title>. <source>Bone Joint J.</source>
<volume>103-b</volume>, <fpage>39</fpage>&#x02013;<lpage>45</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1302/0301-620X.103B1.BJJ-2020-0771.R2</pub-id>
<pub-id pub-id-type="pmid">33380187</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Detecting the presence of bacteria in low-volume preoperative aspirated synovial fluid by metagenomic next-generation sequencing</article-title>. <source>Int. J. Infect. diseases: IJID: Off. Publ. Int. Soc. Infect. Dis.</source>
<volume>99</volume>, <fpage>108</fpage>&#x02013;<lpage>116</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijid.2020.07.039</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Forbes</surname><given-names>B. A.</given-names></name><name><surname>Hall</surname><given-names>G. S.</given-names></name><name><surname>Miller</surname><given-names>M. B.</given-names></name><name><surname>Novak</surname><given-names>S. M.</given-names></name><name><surname>Rowlinson</surname><given-names>M. C.</given-names></name><name><surname>Salfinger</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Practical guidance for clinical microbiology laboratories: mycobacteria</article-title>. <source>Clin. Microbiol. Rev.</source>
<volume>31</volume> (<issue>2</issue>), <elocation-id>e00038-17</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/CMR.00038-17</pub-id>
<pub-id pub-id-type="pmid">29386234</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Clarkson</surname><given-names>S.</given-names></name><name><surname>Phillips</surname><given-names>C. D.</given-names></name><name><surname>Dennis</surname><given-names>D. A.</given-names></name><name><surname>Klatt</surname><given-names>B. A.</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>M. J.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>An enhanced understanding of culture-negative periprosthetic joint infection with next-generation sequencing: A multicenter study</article-title>. <source>J. Bone Joint surgery.</source>
<volume>104</volume>, <fpage>1523</fpage>&#x02013;<lpage>1529</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2106/JBJS.21.01061</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Culture-negative periprosthetic joint infection: is there a diagnostic role for next-generation sequencing</article-title>? <source>Expert Rev. Mol. diagnostics</source>
<volume>20</volume>, <fpage>269</fpage>&#x02013;<lpage>272</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/14737159.2020.1707080</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>mNGS in clinical microbiology laboratories: on the road to maturity</article-title>. <source>Crit. Rev. Microbiol.</source>
<volume>45</volume>, <fpage>668</fpage>&#x02013;<lpage>685</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1080/1040841X.2019.1681933</pub-id>
<pub-id pub-id-type="pmid">31691607</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>L. R.</given-names></name><name><surname>D&#x000e9;ziel</surname><given-names>E.</given-names></name><name><surname>D&#x02019;Argenio</surname><given-names>D. A.</given-names></name><name><surname>L&#x000e9;pine</surname><given-names>F.</given-names></name><name><surname>Emerson</surname><given-names>J.</given-names></name><name><surname>McNamara</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Selection for <italic>Staphylococcus aureus</italic> small-colony variants due to growth in the presence of Pseudomonas aeruginosa</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>103</volume>, <fpage>19890</fpage>&#x02013;<lpage>19895</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.0606756104</pub-id>
<pub-id pub-id-type="pmid">17172450</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Diagnosis of Coxiella burnetii Prosthetic Joint Infection Using mNGS and ptNGS: A Case Report and Literature Review</article-title>. <source>Orthopaedic Surg.</source>
<volume>15</volume>, <fpage>371</fpage>&#x02013;<lpage>376</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/os.13600</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z. D.</given-names></name><name><surname>Zhang</surname><given-names>Z. J.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>W. B.</given-names></name><name><surname>Zhang</surname><given-names>C. J.</given-names></name><name><surname>Fang</surname><given-names>X. Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Pathogenic detection by metagenomic next-generation sequencing in osteoarticular infections</article-title>. <source>Front. Cell. infection Microbiol.</source>
<volume>10</volume>, <elocation-id>471</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2020.00471</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hulleman</surname><given-names>C. W. J.</given-names></name><name><surname>de Windt</surname><given-names>T. S.</given-names></name><name><surname>Veerman</surname><given-names>K.</given-names></name><name><surname>Goosen</surname><given-names>J. H. M.</given-names></name><name><surname>Wagenaar</surname><given-names>F. B. M.</given-names></name><name><surname>van Hellemondt</surname><given-names>G. G.</given-names></name></person-group> (<year>2023</year>). <article-title>Debridement, antibiotics and implant retention: A systematic review of strategies for treatment of early infections after revision total knee arthroplasty</article-title>. <source>J. Clin. Med.</source>
<volume>12</volume> (<issue>15</issue>), <fpage>5026</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3390/jcm12155026</pub-id>
<pub-id pub-id-type="pmid">37568428</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Illingworth</surname><given-names>K. D.</given-names></name><name><surname>Mihalko</surname><given-names>W. M.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name><name><surname>Sculco</surname><given-names>T.</given-names></name><name><surname>McArthur</surname><given-names>B.</given-names></name><name><surname>Bitar</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>How to minimize infection and thereby maximize patient outcomes in total joint arthroplasty: a multicenter approach: AAOS exhibit selection</article-title>. <source>J. Bone Joint surgery.</source>
<volume>95</volume>, <elocation-id>e50</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2106/JBJS.L.00596</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jacovides</surname><given-names>C. L.</given-names></name><name><surname>Kreft</surname><given-names>R.</given-names></name><name><surname>Adeli</surname><given-names>B.</given-names></name><name><surname>Hozack</surname><given-names>B.</given-names></name><name><surname>Ehrlich</surname><given-names>G. D.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Successful identification of pathogens by polymerase chain reaction (PCR)-based electron spray ionization time-of-flight mass spectrometry (ESI-TOF-MS) in culture-negative periprosthetic joint infection</article-title>. <source>J. Bone Joint surgery. Am. volume</source>
<volume>94</volume>, <fpage>2247</fpage>&#x02013;<lpage>2254</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2106/JBJS.L.00210</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jandl</surname><given-names>B.</given-names></name><name><surname>Dighe</surname><given-names>S.</given-names></name><name><surname>Gasche</surname><given-names>C.</given-names></name><name><surname>Makristathis</surname><given-names>A.</given-names></name><name><surname>Muttenthaler</surname><given-names>M.</given-names></name></person-group> (<year>2024</year>). <article-title>Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities</article-title>. <source>Clin. Microbiol. Rev.</source>
<volume>37</volume>, <elocation-id>e0013323</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1128/cmr.00133-23</pub-id>
<pub-id pub-id-type="pmid">38995034</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>B. H.</given-names></name><name><surname>Berg</surname><given-names>R. A.</given-names></name><name><surname>Daley</surname><given-names>J. A.</given-names></name><name><surname>Fritz</surname><given-names>J.</given-names></name><name><surname>Bhave</surname><given-names>A.</given-names></name><name><surname>Mont</surname><given-names>M. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Periprosthetic joint infection</article-title>. <source>Lancet (London England)</source>
<volume>387</volume>, <fpage>386</fpage>&#x02013;<lpage>394</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61798-0</pub-id>
<pub-id pub-id-type="pmid">26135702</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langelier</surname><given-names>C.</given-names></name><name><surname>Kalantar</surname><given-names>K. L.</given-names></name><name><surname>Moazed</surname><given-names>F.</given-names></name><name><surname>Wilson</surname><given-names>M. R.</given-names></name><name><surname>Crawford</surname><given-names>E. D.</given-names></name><name><surname>Deiss</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults</article-title>. <source>Proc. Natl. Acad. Sci. United States America</source>
<volume>115</volume>, <fpage>E12353</fpage>&#x02013;<lpage>e12362</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1073/pnas.1809700115</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Rising challenges in periprosthetic joint infections: a focus on rare pathogens and their clinical implications</article-title>. <source>Front. Cell. infection Microbiol.</source>
<volume>14</volume>, <elocation-id>1451398</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2024.1451398</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>S. M.</given-names></name><name><surname>Vegari</surname><given-names>D.</given-names></name><name><surname>Ho</surname><given-names>A.</given-names></name><name><surname>Zmistowski</surname><given-names>B.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure</article-title>. <source>Clin. orthopaedics related Res.</source>
<volume>469</volume>, <fpage>3049</fpage>&#x02013;<lpage>3054</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11999-011-2030-8</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>T. J.</given-names></name><name><surname>Luo</surname><given-names>W. W.</given-names></name><name><surname>Zhang</surname><given-names>S. S.</given-names></name><name><surname>Xie</surname><given-names>J. Y.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>Y. Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>The clinical application value of multi-site mNGS detection of patients with sepsis in intensive care units</article-title>. <source>BMC Infect. Dis.</source>
<volume>24</volume>, <fpage>920</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12879-024-09822-y</pub-id>
<pub-id pub-id-type="pmid">39232674</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J. W.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Yoon</surname><given-names>J. O.</given-names></name><name><surname>Kim</surname><given-names>J. S.</given-names></name><name><surname>Chang</surname><given-names>J. S.</given-names></name><name><surname>Kim</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Non-tuberculous mycobacterial infection of the musculoskeletal system: pattern of infection and efficacy of combined surgical/antimicrobial treatment</article-title>. <source>Bone Joint J.</source>
<volume>96-b</volume>, <fpage>1561</fpage>&#x02013;<lpage>1565</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1302/0301-620X.96B11.33427</pub-id>
<pub-id pub-id-type="pmid">25371475</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parvizi</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>T. L.</given-names></name><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Higuera</surname><given-names>C.</given-names></name><name><surname>Della Valle</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>A. F.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria</article-title>. <source>J. arthroplasty</source>
<volume>33</volume>, <fpage>1309</fpage>&#x02013;<lpage>1314.e2</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.arth.2018.02.078</pub-id>
<pub-id pub-id-type="pmid">29551303</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parvizi</surname><given-names>J.</given-names></name><name><surname>Zmistowski</surname><given-names>B.</given-names></name><name><surname>Berbari</surname><given-names>E. F.</given-names></name><name><surname>Bauer</surname><given-names>T. W.</given-names></name><name><surname>Springer</surname><given-names>B. D.</given-names></name><name><surname>Della Valle</surname><given-names>C. J.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society</article-title>. <source>Clin. orthopaedics related Res.</source>
<volume>469</volume>, <fpage>2992</fpage>&#x02013;<lpage>2994</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1007/s11999-011-2102-9</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>R.</given-names></name></person-group> (<year>2023</year>). <article-title>Periprosthetic joint infection</article-title>. <source>New Engl. J. Med.</source>
<volume>388</volume>, <fpage>251</fpage>&#x02013;<lpage>262</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1056/NEJMra2203477</pub-id>
<pub-id pub-id-type="pmid">36652356</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rieber</surname><given-names>H.</given-names></name><name><surname>Frontzek</surname><given-names>A.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Periprosthetic joint infection associated with Mycoplasma hominis after transurethral instrumentation in an immunocompetent patient. Unusual or underestimated? A case report and review of the literature</article-title>. <source>Int. J. Infect. diseases: IJID: Off. Publ. Int. Soc. Infect. Dis.</source>
<volume>82</volume>, <fpage>86</fpage>&#x02013;<lpage>88</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijid.2019.03.012</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stoodley</surname><given-names>P.</given-names></name><name><surname>Conti</surname><given-names>S. F.</given-names></name><name><surname>DeMeo</surname><given-names>P. J.</given-names></name><name><surname>Nistico</surname><given-names>L.</given-names></name><name><surname>Melton-Kreft</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Characterization of a mixed MRSA/MRSE biofilm in an explanted total ankle arthroplasty</article-title>. <source>FEMS Immunol. Med. Microbiol.</source>
<volume>62</volume>, <fpage>66</fpage>&#x02013;<lpage>74</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/j.1574-695X.2011.00793.x</pub-id>
<pub-id pub-id-type="pmid">21332826</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>T. L.</given-names></name><name><surname>Kheir</surname><given-names>M. M.</given-names></name><name><surname>Shohat</surname><given-names>N.</given-names></name><name><surname>Tan</surname><given-names>D. D.</given-names></name><name><surname>Kheir</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Culture-negative periprosthetic joint infection: an update on what to expect</article-title>. <source>JB JS Open Access</source>
<volume>3</volume>, <elocation-id>e0060</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2106/JBJS.OA.17.00060</pub-id>
<pub-id pub-id-type="pmid">30533595</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarabichi</surname><given-names>M.</given-names></name><name><surname>Shohat</surname><given-names>N.</given-names></name><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Alvand</surname><given-names>A.</given-names></name><name><surname>Silibovsky</surname><given-names>R.</given-names></name><name><surname>Belden</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2018</year>a). <article-title>Diagnosis of periprosthetic joint infection: the potential of next-generation sequencing</article-title>. <source>J. Bone Joint surgery. Am. volume</source>
<volume>100</volume>, <fpage>147</fpage>&#x02013;<lpage>154</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2106/JBJS.17.00434</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarabichi</surname><given-names>M.</given-names></name><name><surname>Shohat</surname><given-names>N.</given-names></name><name><surname>Goswami</surname><given-names>K.</given-names></name><name><surname>Parvizi</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>b). <article-title>Can next generation sequencing play a role in detecting pathogens in synovial fluid</article-title>? <source>Bone Joint J.</source>
<volume>100-b</volume>, <fpage>127</fpage>&#x02013;<lpage>133</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1302/0301-620X.100B2.BJJ-2017-0531.R2</pub-id>
<pub-id pub-id-type="pmid">29437053</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Roy</surname><given-names>Z.</given-names></name><name><surname>Arumugam</surname><given-names>P.</given-names></name><name><surname>Bertrand</surname><given-names>B. P.</given-names></name><name><surname>Shinde</surname><given-names>D. D.</given-names></name><name><surname>Thomas</surname><given-names>V. C.</given-names></name><name><surname>Kielian</surname><given-names>T.</given-names></name></person-group> (<year>2024</year>). <article-title>Tissue niche influences immune and metabolic profiles to <italic>Staphylococcus aureus</italic> biofilm infection</article-title>. <source>Nat. Commun.</source>
<volume>15</volume>, <fpage>8965</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1038/s41467-024-53353-8</pub-id>
<pub-id pub-id-type="pmid">39420209</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walker</surname><given-names>D. J.</given-names></name><name><surname>Heslop</surname><given-names>P. S.</given-names></name><name><surname>Chandler</surname><given-names>C.</given-names></name><name><surname>Pinder</surname><given-names>I. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Measured ambulation and self-reported health status following total joint replacement for the osteoarthritic knee</article-title>. <source>Rheumatol. (Oxford England)</source>
<volume>41</volume>, <fpage>755</fpage>&#x02013;<lpage>758</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1093/rheumatology/41.7.755</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Miao</surname><given-names>Q.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The clinical value of metagenomic next-generation sequencing in the microbiological diagnosis of skin and soft tissue infections</article-title>. <source>Int. J. Infect. diseases: IJID: Off. Publ. Int. Soc. Infect. Dis.</source>
<volume>100</volume>, <fpage>414</fpage>&#x02013;<lpage>420</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1016/j.ijid.2020.09.007</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Periprosthetic joint infection caused by mycoplasma hominis, diagnosed using metagenomic sequencing</article-title>. <source>Int. J. Gen. Med.</source>
<volume>14</volume>, <fpage>7003</fpage>&#x02013;<lpage>7006</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/IJGM.S330924</pub-id>
<pub-id pub-id-type="pmid">34707391</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiang</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>Infection due to Mycoplasma hominis after left hip replacement: case report and literature review</article-title>. <source>BMC Infect. Dis.</source>
<volume>19</volume>, <fpage>50</fpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1186/s12879-019-3686-z</pub-id>
<pub-id pub-id-type="pmid">30642271</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Dai</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Diagnostic value of metagenomic next-generation sequencing for multi-pathogenic pneumonia in HIV-infected patients</article-title>. <source>Infection Drug resistance</source>
<volume>16</volume>, <fpage>607</fpage>&#x02013;<lpage>618</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.2147/IDR.S394265</pub-id>
<pub-id pub-id-type="pmid">36733920</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Clinical outcomes of culture-negative and culture-positive periprosthetic joint infection: similar success rate, different incidence of complications</article-title>. <source>Orthopaedic Surg.</source>
<volume>14</volume>, <fpage>1420</fpage>&#x02013;<lpage>1427</lpage>. doi:&#x000a0;<pub-id pub-id-type="doi">10.1111/os.13333</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Metagenomic next-generation sequencing assists the diagnosis treatment of fungal osteoarticular infections</article-title>. <source>Front. Cell. infection Microbiol.</source>
<volume>12</volume>, <elocation-id>1072539</elocation-id>. doi:&#x000a0;<pub-id pub-id-type="doi">10.3389/fcimb.2022.1072539</pub-id>
</mixed-citation></ref></ref-list></back></article>